ACF
GHS Report

News Details

GPC - Global Product Compliance

Canadian Consultation on Low Boiling Point Naphthas: Engaging Stakeholders in Regulatory Decision-Making

2024-03-28 Reference source : Health Canada

Chemical industry Cosmetic Products


Health Canada and Environment and Climate Change Canada (ECCC) are currently seeking feedback from industry stakeholders and interested parties on the regulation of low boiling point naphthas (LBPNs). The deadline for comments is May 15, 2024. 

 

Understanding Low Boiling Point Naphthas: Key Considerations and Regulatory Assessment 

In the realm of petrochemicals, low boiling point naphthas (LBPNs) are emerging as a complex group of hydrocarbons that are essential for a variety of industrial applications. Derived from the distillation of crude oil, LBPNs include a wide range of hydrocarbons from C4 to C14 in the carbon chain spectrum. These substances include alkanes, cycloalkanes, alkenes, and aromatic hydrocarbons and their chemical diversity makes them invaluable in the production of gasoline, solvents, and numerous consumer and industrial products. 

Classified as UVCBs (Unknown or Variable Composition, Complex Reaction Products or Biological Materials), the intricate nature of LBPNs presents challenges to their consistent characterization. However, their significant role in fuel blending processes and as components in manufacturing underscores their industrial relevance. 

Health Canada and Environment and Climate Change Canada (ECCC) have classified LBPNs into four distinct subgroups, based on their health effects, presence in consumer products, and aromatic content. These include: 

- Subgroup 1: C9-C14 hydrocarbon solvents 

- Subgroup 2: C9 aromatic hydrocarbon solvents 

- Subgroup 3: C6-C9 aliphatic hydrocarbon solvents 

- Subgroup 4: LBPNs not used in consumer products 

LBPNs are used in a wide range of solvents, viscosity adjustors, and fuel additives, and play a central role in petroleum production, industrial processing and products ranging from lubricants to personal care products. Despite their widespread use, the health and environmental impacts of certain LBPNs require careful management and regulation. 

In a recent draft assessment by Health Canada and the ECCC, 17 out of 27 LBPN substances have been provisionally identified as meeting toxicity criteria under the Canadian Environmental Protection Act (CEPA). This assessment further divides LBPNs into four main categories for regulatory focus and risk management. 

 

Current Regulatory Landscape and Risk Management Initiatives 

In Canada, regulatory action on LBPNs spans several areas including cosmetics, food additives, food packaging, pest control products, and consumer safety. In particular, certain LBPNs are highlighted for their absence from the Cosmetic Ingredient Hotlist and the List of Permitted Food Additives, emphasizing their restricted use in these sectors. Additionally, their use in food packaging and pest control underline the nuanced approach towards ensuring public health and safety. 

Internationally, the regulation of LBPNs varies, with specific restrictions and approvals in the United States and Europe, particularly regarding their use in cosmetics, food-related applications, and environmental emissions. These regulatory frameworks reflect a concerted effort to mitigate health risks while recognizing the essential industrial applications of LBPNs. 

 

Invitation for Stakeholder Engagement 

As the assessment progresses, industry stakeholders, and interested parties are encouraged to participate in the consultation process. The input received will be critical in refining risk management strategies and ensuring a balanced approach to regulating the use of LBPNs use and addressing potential health and environmental impacts. The deadline for comments is May 15, 2024, providing a valuable opportunity to contribute to informed decision-making. 

 

In summary, the evolving landscape of LBPN regulation underscores the importance of these substances in various sectors, while highlighting the need for vigilant risk management to protect public health and the environment. Stakeholder engagement remains a critical component of this process, ensuring comprehensive and effective regulatory action. 

 
 
 



We acknowledge that the above information has been compiled from Health Canada.

<< PREVIOUS BACK NEXT >>
Top